From the Journals

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Share

A comprehensive analysis of over 12,000 Crohn's disease patients revealed similar safety profiles among various treatments, including biologics and a Janus kinase inhibitor, with consistent rates of serious infections, venous thromboembolism, and cardiovascular events across therapies. While serious infection rates varied, ustekinumab showed a lower risk for gastrointestinal infections compared to vedolizumab. Overall findings indicate low event rates, supported by funding from significant health organizations. The study highlights the need for cautious interpretation due to its limitations.

Original Source(s)

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

  • by Doug Brunk

  • February 19, 2026

  • 2 min

Related Content

Income, BMI Linked to Colon Capsule Completion

Danish screening data identify clinical and socioeconomic factors that significantly influence whether colon capsule exams are completed.

Proton Pump Inhibitors and Cancer Risk

Investigators evaluate cancer risk tied to extended acid suppression therapy.

The Unexpected Risks of Liquid Nitrogen Ingestion 

A case report describes gastric perforation following ingestion of a liquid nitrogen–infused drink